Increased plasma plasminogen activator inhibitor-1 levels caused by additional aspirin treatment [3]

Thrombosis and Haemostasis

Volumn 95, Issue 5, 2006, Pages 906-907

  Sakata, Toshiyuki ^a   Kario, Kazuomi ^b  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; COLLAGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; IMMUNOASSAY; INFORMED CONSENT; LETTER; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; WILCOXON SIGNED RANKS TEST;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 33646462310     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-01-0032     Document Type: Letter

References (12)

1. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibits and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
3. Sanderson S, Emery J, Baglin T, et al. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005; 142: 370-80.
4. Cogo A, Ling E, Sturk A, et al. Acetylsalicylic acid inhibits platelet PAI-1 antigen release without affecting circulating PAI-1 antigen in plasma. Ric Clin Lab 1990; 20: 113-7.
5. Husted SE, Kristensen SD, Vissinger H, et al. Intravenous acetylsalicylic acid -dose-related effects on platelet function and fibrinolysis in healthy males. Thromb Haemost 1992; 68: 226-9.
6. Mousa SA, Forsythe MS, Bozarth JM, et al. Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor-1. Cardiology 1993; 83: 367-73.
7. Tohgi H, Takahashi H, Chiba K, et al. Coagulation-fibrinolysis system in poststroke patients receiving antiplatelet medication. Stroke 1993; 24: 801-4.
8. Ono T, Sogabe M, Ogura M, et al. Automated latex photometric immunoassay for total plasminogen activator inhibitor-1 in plasma. Clin Chem 2003; 49: 987-9.
9. Sakata T, Mannami T, Baba S, et al. Potential of free-form TFPI and PAI-1 to be useful markers of early atherosclerosis in a Japanese general population (the Suita Study): association with the intimal-medial thickness of carotid arteries. Atherosclerosis 2004; 176: 355-60.
10. Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-72.
11. Declerck PJ, Alessi MC, Verstreken M, et al. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-5.
12. Podor TJ, Singh D, Chindemi P, et al. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem 2002; 277: 7529-39.